Trial
NCT05368402
Clinical Trial on Ladarixin Adjunctive Therapy to Improve Glycemic Control in Type 1 Diabetes.
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Dompé Farmaceutici S.p.A
Collaborators
—
Condition
Type 1 Diabetes
Intervention
Ladarixin
Why stopped
low recruitment rate
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-02-03